NCT04908865View on ClinicalTrials.gov

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

PHASE4CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

May 23, 2024

Study Completion Date

August 13, 2024

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Belimumab

Belimumab will be administered.

DRUG

Standard therapy

Standard therapy will be continued.

Trial Locations (9)

100045

GSK Investigational Site, Beijing

130021

GSK Investigational Site, Changchun

210011

GSK Investigational Site, Nanjing

215007

GSK Investigational Site, Suzhou

310052

GSK Investigational Site, Hangzhou

361006

GSK Investigational Site, Shanghai

400014

GSK Investigational Site, Chongqing

410007

GSK Investigational Site, Changsha

710054

GSK Investigational Site, Xi'an

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04908865 - Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) | Biotech Hunter | Biotech Hunter